HealthQuill Glucose Metabolism
Denmark’s Novo Nordisk will advance its experimental drug amycretin, in both injection and oral forms, into end-stage trials in weight management based on completed clinical studies, according to a company statement.
Drugs Health Pharma

Novo Nordisk’s obesity drug to begin end-stage trials in early 2026

HQ Team July 13, 2025: Denmark’s Novo Nordisk A/S will advance its experimental drug amycretin, in both injection and oral forms, into end-stage.

Read More